The Serine/Threonine Protein Kinase DCLK1 pipeline drugs market research report outlays comprehensive information on the Serine/Threonine Protein Kinase DCLK1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Serine/Threonine Protein Kinase DCLK1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology which include the indications Colorectal Cancer, and Pancreatic Ductal Adenocarcinoma. It also reviews key players involved in Serine/Threonine Protein Kinase DCLK1 targeted therapeutics development with respective active and dormant or discontinued products.
The Serine/Threonine Protein Kinase DCLK1 pipeline targets constitutes close to five molecules. Out of which, approximately five molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Preclinical, and Discovery stages are 3, and 2 respectively.
Serine/Threonine Protein Kinase DCLK1 overview
Doublecortin-Like Kinase 1 (DCLK1) is a serine/threonine protein kinase that belongs to the protein kinase superfamily. It is characterized by its doublecortin domains, which are involved in microtubule binding and stabilization. DCLK1 plays a significant role in various cellular processes, including neurogenesis, microtubule dynamics, and cell signaling. One of the notable functions of DCLK1 is its involvement in the development and maintenance of neuronal structures. It participates in microtubule assembly and stabilization, contributing to the proper formation and function of neuronal processes, such as axons and dendrites. DCLK1 has been identified as a marker for certain populations of stem cells and progenitor cells, particularly in the gastrointestinal tract. In the context of cancer, DCLK1 has gained attention as a potential cancer stem cell marker and therapeutic target. Its overexpression has been associated with tumor initiation, progression, and resistance to therapy in various cancer types.
For a complete picture of Serine/Threonine Protein Kinase DCLK1’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
